Moral hazard in healthcare is the problem that when a third party, an insurer or the government, pays the bill, patients and providers no longer bear the full cost at the point of use, so they over consume and quantity demanded is pushed beyond the efficient level. That is the economic case for co payments and price controls, and it is the direction Singapore's Health Minister Mr Ong Ye Kung has taken to control healthcare costs. The analysis is sound. The important distinction, though, is that moral hazard applies to discretionary, price sensitive care. It does not apply to rare, unpredictable, catastrophic conditions, where the patient did nothing to over consume and the event is not a matter of choice. Those are exactly the events that insurance and pooled risk exist to cover, so the right response there is full subsidy or risk pooling, not co payment.
Healthcare is the single richest market failure case study on the A level syllabus, because nearly every failure you learn lives inside it at once. So when Singapore's Health Minister Mr Ong Ye Kung pushes to control healthcare costs and tackle over consumption, an economics student should not read it as a political headline. It is an applied microeconomics problem, and a well set exam question. The story is worth telling properly, because the economics behind the policy is genuinely strong, and because there is one important place where that same economics points the other way.
The story: controlling the cost of care
The policy direction is straightforward to state. Healthcare spending in Singapore, as in every ageing high income society, has been climbing faster than incomes, and the Ministry of Health under Mr Ong Ye Kung has set out to slow that climb: to keep premiums and bills affordable, to push back on prices that drift upward, and to address the over consumption and over provision that a heavily subsidised, heavily insured system tends to produce. The instruments are familiar, co payments, claim limits, price benchmarks and gatekeeping, and they are all, at bottom, ways of putting some cost signal back in front of the patient and the provider. To see why that is the right instinct, you have to see the market failure it is aimed at.
The economics: a market riddled with failure
Healthcare is not one market failure but a cluster of them, sitting on top of one another. The first, and the one the minister's direction targets most directly, is moral hazard. When a third party pays, an insurer or the government, the patient no longer faces the full price at the point of use. The marginal cost to the patient of one more consultation, one more scan, one more night in a ward, falls toward zero, even though the marginal cost to society does not. Predictably, quantity demanded rises beyond the point where the marginal benefit to the patient equals the marginal cost of providing it. The result is over consumption: care is used past the efficient level, not because anyone is acting dishonestly, but because the price they personally face has been switched off.
- Moral hazard
- When a party is shielded from the full cost of its actions, here because a third party pays the bill, it changes its behaviour and consumes more than it otherwise would. In healthcare it drives over consumption above the efficient level.
- Merit good
- A good, like healthcare, that society judges people will under consume relative to the benefit it brings, partly because of positive externalities, so there is a case for subsidy or provision.
- Asymmetric information
- One side of a transaction knows more than the other. In health insurance the patient knows their own risk better than the insurer, which leads to adverse selection.
The second failure is asymmetric information, and it bites hardest in the insurance market that sits behind the care. The patient knows their own health and habits far better than the insurer does. The high risk are the keenest to buy generous cover, the low risk drop out as premiums rise to cover them, and the pool tilts steadily toward the sick. That is adverse selection, and left alone it can unravel a voluntary insurance market entirely. It is one reason healthcare is rarely left to a free market anywhere in the world.
The third is that healthcare is a merit good with positive externalities and a strong equity dimension. A healthy population is more productive and less infectious; treating one person's illness can spare others theirs. People also under appreciate, or cannot afford, care that delivers benefits to society beyond themselves. So the social marginal benefit of healthcare sits above the private, and a pure market would under provide it. This is the countervailing force, the reason we do not simply price healthcare like any other good and let the market clear.
Hold those three together and the minister's direction reads cleanly in economic terms. Where a system over insures and over subsidises discretionary care, moral hazard dominates and you get over consumption, so a co payment or a price control restores some of the missing cost signal and pulls quantity back toward the efficient level. That is sound microeconomics, not austerity. A co payment is simply the price mechanism doing the rationing job that a zero point of use price had switched off.
Mr Toh's take
Here is where I will put my own view on the table, because I think the economics actually supports a sharper position than the debate usually allows. Mr Ong Ye Kung's move to control healthcare prices and tackle moral hazard is correct, and the economics behind it is sound. When a third party pays, people do over consume, providers do over service, and a co payment is a perfectly respectable way to put the cost signal back. I have no quarrel with any of that, and as an economist I would defend it.
But I think we should be just as rigorous about the other side of the same argument. If the case for a co payment rests entirely on moral hazard, then where there is genuinely no moral hazard, the case for a co payment falls away with it. So why are we not fully subsidising the rare, unpredictable, high cost conditions, the ones where there is no element of over consumption and no element of choice? Think of the generic case of a rare disease: a patient who did nothing to bring it on, cannot consume more or less of it by choosing to, and faces a catastrophic bill through sheer bad luck of the draw. There is no behaviour there for a co payment to correct. That, to me, is exactly where the case for full subsidy or pooled insurance is strongest, and it deserves the same clear economic thinking we are rightly applying to over consumption. This is not a criticism of the direction. It is the same logic, carried all the way through.
A healthcare question is a market failure goldmine, so do not stop at one failure. Define moral hazard precisely, show on a diagram why third party payment pushes quantity demanded beyond the efficient level, and explain why a co payment or price control restores part of the efficient outcome. Then take the marks at the top by distinguishing the cases. A model sentence: "Where consumption of healthcare is discretionary and price sensitive, third party payment creates moral hazard and over consumption, so a co payment that restores a cost signal is efficiency enhancing; but where the condition is rare, unpredictable and catastrophic, there is no moral hazard to correct, and the equity and risk pooling case for full coverage dominates instead." Distinguishing the two cases is exactly the evaluative move that separates a top band answer from a competent one.
| Discretionary, price sensitive care | Rare, unpredictable, catastrophic care | |
|---|---|---|
| Is there moral hazard? | Yes, consumption rises when the patient does not face the price | No, the patient cannot choose to consume more or less of the event |
| Why | Care is elective and quantity responds to the point of use price | The condition is bad luck, not a choice, so behaviour is not the driver |
| Right policy response | Co payment and price controls, to restore the cost signal | Full subsidy or risk pooling, to cover an unpredictable catastrophic loss |
| Economic rationale | Pull quantity demanded back toward the efficient level | This is precisely the role insurance and pooled risk exist to perform |
The whole argument on one grid. The moral hazard case and the co payment response are sound for the left column; for the right column there is no moral hazard to correct, so the case for full coverage dominates. Reading across the rows is the high level distinction an evaluation question rewards.
Read the grid across rather than down. The left column is the minister's territory, and the economics backs the policy: discretionary care responds to price, so a co payment rations it sensibly. The right column is the exception that the same economics carves out. A rare, unpredictable, catastrophic condition is not a behaviour, it is a draw of the dice, and you cannot deter a draw of the dice with a co payment. Insurance and risk pooling exist for precisely that column, to spread an unpredictable, ruinous loss across many people so no single unlucky person bears it alone. To put a co payment there is to ask the patient to pay for being unlucky, which neither corrects a behaviour nor serves equity.
You cannot deter bad luck with a co payment. Moral hazard is about choices, and a rare catastrophic illness is not a choice.
So the constructive conclusion is not to weaken the cost control direction, it is to complete it. Tackle moral hazard hard where moral hazard exists, in the broad mass of discretionary, price sensitive care, and at the same time cover fully, through subsidy or pooled insurance, the narrow set of rare and catastrophic conditions where there is no moral hazard to tackle. The two policies are not in tension. They come from the same economics, applied honestly to two different kinds of case. That is the analysis I would want a strong A level student, and a strong policymaker, to be able to make.
- Moral hazard is real and the policy is sound. When a third party pays, patients and providers over consume, so co payments and price controls that restore a cost signal pull quantity back toward the efficient level.
- Healthcare stacks several market failures. Moral hazard, asymmetric information and adverse selection in insurance, and healthcare as a merit good with positive externalities and an equity dimension.
- The key distinction is choice. Moral hazard applies to discretionary, price sensitive care; it does not apply to rare, unpredictable, catastrophic conditions, which are bad luck, not behaviour.
- The right tool differs by case. Co payment where consumption is elective; full subsidy or risk pooling where the loss is catastrophic and unchosen, because that is what insurance exists to cover.
- In the exam, distinguish the cases. Defining moral hazard earns the lower marks; separating where it applies from where it does not is the evaluative move that reaches the top band.
Want this on paper? Grab the free 112 page Summary and Diagrams pack.
Frequently asked
What is moral hazard in healthcare?
Moral hazard in healthcare is the tendency to consume more medical care than is efficient when a third party, an insurer or the government, pays the bill, so the patient does not face the full price at the point of use. Because the marginal cost to the patient of an extra consultation, scan or hospital night falls toward zero while the cost to society does not, quantity demanded is pushed beyond the level where marginal benefit equals marginal cost. The result is over consumption and over provision. It is not dishonesty, it is a predictable response to a price that has been switched off, and it is the central reason co payments and price controls are used as a corrective.
Why does insurance cause over consumption of healthcare?
Insurance works by having many people pool their contributions so the unlucky few who fall ill are covered, which means that at the moment of treatment the insured patient pays little or nothing directly. That is precisely what makes insurance valuable for catastrophic risk, but it also removes the price signal for routine, discretionary care. Once care is close to free at the point of use, both patients and providers face weak incentives to economise, so more is consumed and supplied than is efficient. This is moral hazard, and it is why most insurance systems use co payments, deductibles and claim limits to keep some cost signal in front of the user for elective care.
Should healthcare be fully subsidised?
It depends on the type of care, and that distinction is the whole point. For discretionary, price sensitive care, full subsidy would maximise moral hazard and over consumption, so a co payment that restores a cost signal is the more efficient design, which is the economic logic behind Singapore's direction of controlling costs. But for rare, unpredictable and catastrophic conditions, where the patient did nothing to over consume and the event is a matter of bad luck rather than choice, there is no moral hazard to correct, and the equity and risk pooling case for full subsidy or pooled insurance is much stronger. The honest answer is that different cases call for different policies, not a single rule for everything.
Is healthcare a merit good?
Yes. Healthcare is treated as a merit good because society judges that people, left to themselves, would under consume it relative to the benefit it delivers, partly because of positive externalities. A healthier, treated population is more productive and less likely to spread infectious disease, so the social marginal benefit of healthcare sits above the private marginal benefit, and a pure free market would under provide it. That merit good and externality argument is the countervailing force to moral hazard: it is why healthcare is subsidised and provided rather than left to the market, even as policymakers use co payments to restrain the over consumption that heavy subsidy can encourage.
Does the moral hazard argument apply to rare diseases?
Generally not, and that is the crucial exception. The moral hazard argument applies to care that is discretionary and responds to price, because there a co payment can deter unnecessary consumption. A rare, unpredictable and catastrophic condition is different in kind: the patient cannot choose to consume more or less of it, did nothing to bring it on, and faces a ruinous bill through sheer bad luck. There is no over consuming behaviour for a co payment to correct, so the moral hazard case for cost sharing simply does not hold. These are exactly the events that insurance and pooled risk exist to cover, which is why the case for full subsidy or risk pooling is strongest precisely where moral hazard is absent.
U to E in one month
"Mr Toh helped me go from U to E in just one month since I started tuition, and since then the grades have just been going up."Daniel Heng
The standard, every week.
One essay or case study a week, personally marked with a worked model and a video walkthrough, from materials written by the author of the H1 and H2 TYS answer keys sold at Popular. This is the core JC1 and JC2 programme.
Weekly, marked, everything included
- A marked essay or case study each week
- Worked model plus a video walkthrough
- Onsite, live Zoom or recordings